Cedars Sinai enrolls first patient in a study that uses AlloSure to characterize patient response to therapy
BRISBANE, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces a partnership with the Cedars-Sinai Comprehensive Transplant Center to study the use of AlloSure to characterize response to therapy in kidney transplant recipients that are being treated for chronic antibody-mediated rejection (ABMR).
ABMR is recognized as the leading cause of late kidney transplant failure. Long-term graft survival has not improved, primarily due to late diagnosis and lack of effective therapeutic options. Cedars-Sinai is testing an Interleukin-6 blockade, tocilizumab, as a treatment for patients with ABMR. They will use AlloSure to optimize the therapy regime.
“This study will give us the opportunity to evaluate a novel biomarker with AlloSure in an effort to optimize management of kidney transplant recipients being treated for chronic ABMR,” said Dr. Edmund Huang, a transplant nephrologist at Cedars-Sinai and principal investigator for this study. “Chronic ABMR continues to have a significant negative impact on long-term graft survival, although treatment with tocilizumab has shown great promise. We are very excited to see how AlloSure may be able to further guide tocilizumab treatment in these patients and improve long-term outcomes.”
“We are glad to sponsor this investigator initiated trial at Cedars Sinai to help evaluate the efficacy of this new biologics-based drug therapy in a patient group that needs better solutions,” said Jim Yee, Chief Medical Officer, CareDx. “Many physicians already have begun to use AlloSure to assess responses to rejection treatment. This study will add knowledge specifically for tocilizumab to the body of evidence that is continuing to accumulate for such utility with AlloSure.”
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products along the pre- and post-transplant testing continuum, and is the leading provider of genomics-based information for transplant patients.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements, including expectations regarding the Company’s fiscal 2019 revenue, achievement of our financial and operational goals and our prospects. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including general economic and market factors, among others discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed by CareDx with the SEC on March 6, 2019 and the periodic reports that CareDx has subsequently filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Chief Commercial Officer
Integrated Corporate Relations, Inc.